{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T12:11:23Z","timestamp":1768738283834,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00277-023-05519-5","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T04:27:48Z","timestamp":1699504068000},"page":"525-532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: two-case report"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1971-0619","authenticated-orcid":false,"given":"Shengxuan","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaoyao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"5519_CR1","doi-asserted-by":"crossref","unstructured":"Iacobucci I, Kimura S, Mullighan CG (2021) Biologic and therapeutic implications of genomic alterations in acute lymphoblastic leukemia. J Clin Med 10(17):3792","DOI":"10.3390\/jcm10173792"},{"issue":"12","key":"5519_CR2","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1182\/blood.V80.12.2983.2983","volume":"80","author":"CA Westbrook","year":"1992","unstructured":"Westbrook CA, Hooberman AL, Spino C et al (1992) Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 80(12):2983\u20132990","journal-title":"Blood"},{"issue":"3","key":"5519_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood.V99.3.863","volume":"99","author":"L Annino","year":"2002","unstructured":"Annino L, Vegna ML, Camera A et al (2002) Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 99(3):863\u2013871","journal-title":"Blood"},{"issue":"20","key":"5519_CR4","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","volume":"22","author":"X Thomas","year":"2004","unstructured":"Thomas X, Boiron JM, Huguet F et al (2004) Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 22(20):4075\u20134086","journal-title":"J Clin Oncol"},{"key":"5519_CR5","doi-asserted-by":"crossref","unstructured":"Saleh K, Fernandez A, Pasquier F (2022) Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Cancers 14(7):1805","DOI":"10.3390\/cancers14071805"},{"issue":"9","key":"5519_CR6","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836\u2013847","journal-title":"N Engl J Med"},{"issue":"14","key":"5519_CR7","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M et al (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131(14):1522\u20131531","journal-title":"Blood"},{"issue":"6","key":"5519_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","volume":"123","author":"AK Fielding","year":"2014","unstructured":"Fielding AK, Rowe JM, Buck G et al (2014) UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 123(6):843\u2013850","journal-title":"Blood"},{"issue":"2","key":"5519_CR9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/bloodadvances.2021004607","volume":"6","author":"I Sugiura","year":"2022","unstructured":"Sugiura I, Doki N, Hata T et al (2022) Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv 6(2):624\u2013636","journal-title":"Blood Adv"},{"issue":"17","key":"5519_CR10","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Fo\u00e0","year":"2020","unstructured":"Fo\u00e0 R, Bassan R, Vitale A et al (2020) Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med 383(17):1613\u20131623","journal-title":"N Engl J Med"},{"issue":"12","key":"5519_CR11","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"WS Huang","year":"2010","unstructured":"Huang WS, Metcalf CA, Sundaramoorthi R et al (2010) Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 53(12):4701\u20134719","journal-title":"J Med Chem"},{"issue":"26","key":"5519_CR12","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","volume":"114","author":"FE Nicolini","year":"2009","unstructured":"Nicolini FE, Mauro MJ, Martinelli G et al (2009) Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood 114(26):5271\u20135278","journal-title":"Blood"},{"issue":"18","key":"5519_CR13","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.1182\/bloodadvances.2022007764","volume":"6","author":"JM Ribera","year":"2022","unstructured":"Ribera JM, Garc\u00eda-Calduch O, Ribera J et al (2022) Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv 6(18):5395\u20135402","journal-title":"Blood Adv"},{"key":"5519_CR14","doi-asserted-by":"crossref","unstructured":"Honglan Q, Dongxu G, Xiaoyu H et al (2022) A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia. Front Oncol 12:1036437","DOI":"10.3389\/fonc.2022.1036437"},{"key":"5519_CR15","doi-asserted-by":"crossref","unstructured":"Qian J, Zongru L, Yazhen Q et al (2022) Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial. J Hematol Oncol 15(1):159","DOI":"10.1186\/s13045-022-01369-2"},{"key":"5519_CR16","doi-asserted-by":"crossref","unstructured":"Elias J, Koller PB, Oehler VG et al (2022) Olverembatinib (HQP1351) overcomes ponatinib resistance in patients with heavily pretreated\/refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 140(S1):200\u2013202","DOI":"10.1182\/blood-2022-162387"},{"issue":"11","key":"5519_CR17","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1634\/theoncologist.2018-0179","volume":"23","author":"ED Pulte","year":"2018","unstructured":"Pulte ED, Vallejo J, Przepiorka D et al (2018) FDA Supplemental approval: blinatumomab for treatment of relapsed and refractory precursor B cell acute lymphoblastic leukemia. Oncologist 23(11):1366\u20131371","journal-title":"Oncologist"},{"issue":"16","key":"5519_CR18","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","volume":"35","author":"G Martinelli","year":"2017","unstructured":"Martinelli G, Boissel N, Chevallier P et al (2017) Complete hematologic and molecular response in adult patients with relapsed\/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol 35(16):1795\u20131802","journal-title":"J Clin Oncol"},{"key":"5519_CR19","doi-asserted-by":"crossref","unstructured":"Chunxiao L, Xiang Z, Liping M et al (2023) Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases. Leuk Lymphoma 64(6):1208\u20131211","DOI":"10.1080\/10428194.2023.2197534"},{"key":"5519_CR20","doi-asserted-by":"crossref","unstructured":"Xu T, Qin W, Guo C et al (2022) Novel third-generation tyrosine kinase inhibitor for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a case study. Anti-Cancer Drugs 34(4):599\u2013604","DOI":"10.1097\/CAD.0000000000001455"},{"key":"5519_CR21","doi-asserted-by":"crossref","unstructured":"Xiaolan L, Jingliao Z, Fang L et al (2023) Olverembatinib treatment in pediatric patients with relapsed Philadelphia-chromosome-positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 23(9):660\u2013666","DOI":"10.1016\/j.clml.2023.04.012"},{"key":"5519_CR22","doi-asserted-by":"publisher","first-page":"S204","DOI":"10.1016\/S2152-2650(22)01203-4","volume":"22","author":"FG Haddad","year":"2022","unstructured":"Haddad FG, Kantarjian H, Short NJ et al (2022) ALL-424 updated results from the phase II study of blinatumomab in combination with ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 22:S204","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5519_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.leukres.2019.02.009","volume":"79","author":"AC King","year":"2019","unstructured":"King AC, Pappacena JJ, Tallman MS et al (2019) Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia. Leuk Res 79:27\u201333","journal-title":"Leuk Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05519-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05519-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05519-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T07:05:06Z","timestamp":1705647906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05519-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["5519"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05519-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"assertion":[{"value":"26 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of the Lan Zhou University (ethics approval number: LDYYLL2023-299).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from the parents. The participant has consented to the submission of the case report to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}